US2002002166A1PendingUtilityA1

Use of MKC-442 in combination with other antiviral agents

36
Priority: Apr 7, 1997Filed: Aug 14, 2001Published: Jan 3, 2002
Est. expiryApr 7, 2017(expired)· nominal 20-yr term from priority
Inventors:Phillip A. FurmanCary P. MoxhamDavid W. BarryKatyna Borroto-Esoda
A61P 37/04A61K 31/505A61P 31/18A61K 31/513A61K 45/06
36
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Use of MKC-442 in combination with other antiviral agents for the treatment of patients infected with HIV is disclosed.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . A method for the treatment of a patient infected with HIV, comprising administering an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a protease inhibitor, or its pharmaceutically acceptable salt.  
     
     
         2 . A method for the treatment of a patient infected with HIV, comprising administering an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a compound selected from the group consisting of: indinavir, nelfinavir, saquinavir, amprenavir, and DMP-450 or its pharmaceutically acceptable salt.  
     
     
         3 . The method of  claim 2 , wherein the compound is indinavir.  
     
     
         4 . The method of  claim 2 , wherein the compound is nelfinavir.  
     
     
         5 . The method of  claim 2 , wherein the compound is saquinavir.  
     
     
         6 . The method of  claim 2 , wherein the compound is amprenavir.  
     
     
         7 . The method of  claim 2 , wherein the compound is DMP-450.  
     
     
         8 . A method for the treatment of a patient infected with HIV, comprising administering an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a compound selected from the group consisting of abacavir, FTC, or 3TC or its pharmaceutically acceptable salt.  
     
     
         9 . The method of  claim 8 , wherein the compound is abacavir.  
     
     
         10 . The method of  claim 8 , wherein the compound is FTC.  
     
     
         11 . The method of  claim 8 , wherein the compound is 3TC.  
     
     
         12 . A method for the treatment of a patient infected with HIV, comprising administering an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a compound selected from the group consisting of DMP-266, delavirdine, and nevirapine or its pharmaceutically acceptable salt.  
     
     
         13 . The method of  claim 12 , wherein the compound is DMP-266.  
     
     
         14 . The method of  claim 12 , wherein the compound is delavirdine.  
     
     
         15 . The method of  claim 12 , wherein the compound is nevirapine.  
     
     
         16 . A pharmaceutical composition for the treatment of a patient infected with HIV, comprising an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination with a protease inhibitor, or its pharmaceutically acceptable salt.  
     
     
         17 . A pharmaceutical composition for the treatment of a patient infected with HIV, comprising an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a compound selected from the group consisting of: indinavir, nelfinavir, saquinavir, amprenavir, and DMP-450 or its pharmaceutically acceptable salt.  
     
     
         18 . The composition of  claim 17 , wherein the compound is indinavir.  
     
     
         19 . The composition of  claim 17 , wherein the compound is nelfinavir.  
     
     
         20 . The composition of  claim 17 , wherein the compound is saquinavir.  
     
     
         21 . The composition of  claim 17 , wherein the compound is amprenavir.  
     
     
         22 . The composition of  claim 17 , wherein the compound is DMP-450.  
     
     
         23 . A pharmaceutical composition for the treatment of a patient infected with HIV, comprising an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination or alternation with a compound selected from the group consisting of abacavir, FTC, or 3TC or its pharmaceutically acceptable salt.  
     
     
         24 . The composition of  claim 8 , wherein the compound is abacavir.  
     
     
         25 . The composition of  claim 8 , wherein the compound is FTC.  
     
     
         26 . The composition of  claim 8 , wherein the compound is 3TC.  
     
     
         27 . A pharmaceutical composition for the treatment of a patient infected with HIV, comprising an effective treatment amount of MKC-442 or its pharmaceutically acceptable salt in combination with a compound selected from the group consisting of DMP-266, delavirdine, and nevirapine or its pharmaceutically acceptable salt.  
     
     
         28 . The composition of  claim 27 , wherein the compound is DMP-266.  
     
     
         29 . The composition of  claim 27 , wherein the compound is delavirdine.  
     
     
         30 . The composition of  claim 27 , wherein the compound is nevirapine.

Join the waitlist — get patent alerts

Track US2002002166A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.